![[LIN Q2 2026 Earnings Call] Record $9.3B Sales, 10% EPS Growth Mask Lincare Margin Squeeze, Prompting Strategic Review](https://time.news/wp-content/uploads/2026/08/aHR0cHM6Ly9pbWcuYmdvLm9uZS9uZXdzLWltYWdlL2Vhcm5pbmdzX2NhcmQvMjAyNi0wNy9VU19MSU5fMjAyNi0wNy0zMV8xNzg1NTEyOTQyLndlYnA.jpg "Linde Reports Record Q2 2026 Sales Amid Lincare Margin Pressures")
Linde plc reported record second-quarter 2026 sales of $9.3 billion and adjusted earnings per share of $4.50 on July 31, 2026. Despite these gains, the company is reviewing the strategic fit of its Lincare U.S. home care business after persistent margin pressures dragged down overall profitability.
The financial results for Linde plc presented a sharp divide between a booming industrial core and a struggling healthcare segment. While consolidated sales grew 9% to $9.3 billion and adjusted earnings per share (EPS) climbed 10% to $4.50, the company’s operating margins contracted by 60 basis points to 29.5% year-over-year. According to the July 31, 2026, earnings release, net income for the second quarter was $1,928 million, and diluted earnings per share were $4.15, representing increases of 9% and 11%, respectively. Adjusted net income, excluding Linde AG purchase accounting impacts, was $2,089 million, up 8% versus the prior year.
This margin dip persisted even after accounting for cost pass-throughs, which would have limited the decline to 30 basis points. CEO Sanjiv Lamba attributed this shortfall primarily to Lincare, the U.S. home healthcare arm that represents roughly 23% of the Americas healthcare revenue. In his opening remarks on the July 31 earnings call, Lamba stated, We are not satisfied with our margin performance for this quarter,
setting a frank tone for the session.
The Lincare Margin Squeeze and Strategic Review
Lincare provides at-home respiratory and oxygen therapies, but the business has been hampered for years by labor cost inflation and shifts in reimbursement policies. Though a new management team began pruning the portfolio last year, Lamba noted that these efforts simply has not been enough to overcome the continued headwinds.
We continue to evaluate the strategic fit of this U.S. home care business,
Lamba noted, as the company determines if the segment still deserves a place in the portfolio.
The financial drag from Lincare is substantial. During the earnings call, CFO Matt White addressed a question from JPMorgan’s Jeff Zekauskas, whose model had assumed a $30 million quarterly headwind. White responded, It’s probably higher.
The contrast is stark: Lamba told BNP Paribas analyst Laurent Favre that The Americas business, ex the U.S. home care or Lincare business would be up 20 basis points on margin.
This indicates that while the home care business is a liability, the core industrial gas engine in the Americas is expanding profitability, buoyed by double-digit hard goods sales and a nascent manufacturing recovery in the United States.
Electronics Boom and the $8.1 Billion Backlog
Outside of healthcare, Linde is experiencing a surge in demand driven by AI-related hardware and semiconductor fab expansions. The company secured a $1 billion electronics contract in the U.S. to supply advanced-node fabs, pushing the sale-of-gas project backlog to a record $8.1 billion.
The electronics sector was the company’s fastest-growing end market this quarter, with sales increasing 18% year-over-year.
Regional Performance and 2026 Guidance
Linde’s growth was distributed unevenly across its global segments. Underlying sales overall increased 4%, split evenly between 2% price attainment and 2% volumes, primarily in electronics, manufacturing and chemicals & energy end markets. Acquisitions contributed a 1% increase in sales.
| Region | Sales | Sales Change (YoY) | Operating Profit Margin |
|---|---|---|---|
| Americas | $4,083 million | +7% | 31.2% |
| APAC | $1,870 million | +13% | 28.4% |
| EMEA | $2,303 million | +7% | 35.7% |
In the Americas, underlying sales grew 4%, with double-digit growth in “hard goods” such as welding equipment and cylinders. Lamba described this as a good signal of manufacturing recovery in the U.S.
The company’s cash flow remains a focal point. Second-quarter operating cash flow was $2,271 million, up 3% versus the prior year. After capital expenditures of $1,438 million, free cash flow was $833 million. During the quarter, the company returned $1,590 million to shareholders.
Linde’s current financial outlook includes the following projections:
- Q3 2026 Adjusted EPS: Expected range of $4.45 to $4.55 (6–8% growth).
- Full-Year 2026 Adjusted EPS: Range of $17.70 to $17.90 (8–9% growth).
- Capital Expenditures: Expected between $5.5 billion and $6.0 billion.
The company’s ability to maintain its long-term trajectory now depends on its willingness to act on the Lincare review. While the record-breaking industrial backlog provides a massive cushion, the persistent 60-basis-point drag on margins suggests that the “strategic fit” of the home care business has become a primary point of friction for shareholders.
